Intercontinental Exchange Inc (ICE) Stock News

Robbins Geller announces a class action lawsuit against Zoetis Inc. for alleged securities violations. The lawsuit claims Zoetis made false statements about its flagship products including Librela, Simparica Trio, Apoquel, and Cytopoint, failing to disclose weakening demand, market share losses to competitors, and increased competitive pressures. Investors who purchased ZTS securities between January 14, 2025 and May 6, 2026 can seek appointment as lead plaintiff by July 27, 2026.

Los Angeles sheriff says ICE enforcement not expected at World Cup matches  Reuters

Stewart Information Services Corporation (NYSE: STC) announced a cash dividend of $0.525 per share for Q2 2026, payable on June 30, 2026, to shareholders of record as of June 15, 2026. The global real estate services company continues its dividend distribution to common stockholders.

Rosen Law Firm has issued deadline notices for securities class action lawsuits against Gossamer Bio, Upstart Holdings, and POET Technologies. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines. The lawsuits allege false and misleading statements regarding clinical trial design and other material facts.

Rosen Law Firm is notifying investors in Upstart Holdings, Inc. (NASDAQ: UPST) of a June 8, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Upstart made false and misleading statements regarding its Model 22 AI risk assessment tool, claiming it frequently overreacted to negative macroeconomic signals, overstated accuracy, and negatively impacted revenue results, rendering the company's 2025 revenue guidance unreliable.

98% Year-Over-Year Revenue Growth; Company Achieves Net Income Profitability; Secures Two Landmark Global Enterprise Agreements VANCOUVER, BC , May 28, 2026 /CNW/ - RESAAS Services Inc. ("RESAAS" or "the Company") (TSXV: RSS ) (OTCQB: RSASF ), a technology company modernizing collaboration, payments, and data exchange across the global real estate industry, today announced its financial results for the first quarter ended March 31, 2026. The Company delivered a record revenue quarter on a year-over-year basis, achieved net profitability, and expanded its enterprise client roster with two globally recognized real estate brands, underscoring the growing commercial validation of its platform. Q1 2026 FINANCIAL & OPERATIONAL HIGHLIGHTS Revenue of $302,470 in Q1 2026, representing 98% growth year-over-year compared to $152,681 in Q1 2025 Net income of $8,627 in Q1 2026, a $77,672 improvement versus a net loss of $(69,045) in Q1 2025 — marking a significant inflection toward profitability Positive operating cash flow of $6,593 for the quarter Cash position increased to $63,373 at March 31, 2026, up from $42,527 at December 31, 2025, driven by revenue collections Working capital deficiency improved by $15,260 quarter-over-quarter to $(891,312) at March 31, 2026 Savills, a leading global real estate services firm, selected RESAAS to power its new global referral platform (February 2026) Chestertons, an internationally recognized real estate brand, selected RESAAS to power its global referral platform (March 2026) Snowflake integration launched, enabling enterprise customers to synchronize RESAAS data into Snowflake's AI Data Cloud Subsequent to quarter-end: closed a $1,800,000 non-brokered private placement at $0.45 per share (April 20, 2026), strengthening the balance sheet FINANCIAL RESULTS Selected Financial Data (CAD$) Q1 2026 Q1 2025 Revenue $302,470 $152,681 Net Inc

Universal Health Services, Inc. (NYSE:UHS) announced that its Board of Directors approved a cash dividend of $0.20 per share payable on June 18, 2026 to shareholders of record as of June 8, 2026.

Girard Sharp LLP is investigating potential securities claims on behalf of former Discover Financial Services investors who received Capital One shares in the May 2025 acquisition. Capital One's stock price has declined since the merger closed. The firm is also investigating similar claims for Blue Owl Capital Corp. III and Blue Owl Technology Finance Corp. II investors.

Girard Sharp LLP is investigating potential securities claims on behalf of former investors in Blue Owl Capital Corp. III and Blue Owl Technology Finance Corp. II who received shares in their respective merger counterparts. Blue Owl Capital's shares have declined over 21% since January 2025, while Blue Owl Technology's shares have fallen over 30% since their June 2025 NYSE listing. The investigation focuses on potential undisclosed issues with the funds' investment portfolios.

Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.

A class action lawsuit has been filed against Stellantis N.V. for allegedly making false statements about its electrification market opportunities and earnings growth. The company announced a €22.2 billion business reset in February 2026, causing its stock to fall over 23%. Investors who purchased shares between February 26, 2025 and February 5, 2026 can seek appointment as lead plaintiff by June 8, 2026.

Girard Sharp LLP is investigating potential securities claims on behalf of former investors in multiple merger transactions, including Capital One's acquisition of Discover (May 2025), Blue Owl Capital Corp. mergers, and Pinnacle Financial Partners' merger with Synovus (January 2026). The investigations were prompted by significant stock price declines following these merger closings.

Girard Sharp LLP is investigating potential securities claims on behalf of former investors of Blue Owl Capital Corp. III and Blue Owl Technology Finance Corp. II who received shares in merger transactions. Blue Owl Capital's shares have declined over 21% since January 2025, while Blue Owl Technology's shares have fallen over 30% since its June 2025 NYSE listing. The investigation focuses on potential undisclosed issues with the funds' investment portfolios.

Law firm Brodsky & Smith is investigating potential breaches of fiduciary duty by InMed Pharmaceuticals' Board of Directors regarding the company's sale to Mentari Therapeutics. The investigation focuses on whether the Board conducted a fair process and whether shareholders are receiving fair value, with InMed shareholders expected to own approximately 1.51% of the combined entity.

Bakkt Inc. (NYSE: BKKT ) shares jumped 16.17% to $10.13 after the bell on Monday, after Securities and Exchange Commission filings disclosed insider activity. Insider Activity Director Michael Alfred , through the Las Vegas-based hedge fund Alpine Fox LP , bought 365,000 shares on May 15 at a weighted average price of $8.34 per share. He then purchased another 220,000 shares on May 18 at $8.20 per share. The two transactions totaled about 585,000 shares valued at approximately $4.85 million. Following the purchases, Alfred indirectly owns 625,000 shares. According to a separate SEC filing, CEO Akshay Sudhir Naheta exercised 33,557 committed stock options on May 15 at $10 per share, for a total value of about $335,570. The transaction was carried out under a pre-established Rule 10b5-1 plan, an SEC-approved trading arrangement that allows corporate insiders to buy or sell shares on a fixed schedule while helping protect them from insider trading liability. What You Should Know On May 11, Bakkt reported first-quarter 2026 revenue of $243.59 million, down 77.1% ... Full story available on Benzinga.com

Rosen Law Firm reminds investors of ODDITY Tech Ltd. (NASDAQ: ODD) of the May 11, 2026 deadline to become lead plaintiff in a securities class action lawsuit. The lawsuit alleges that ODDITY made false statements regarding its business performance, specifically failing to disclose that an algorithm change by its largest advertising partner diverted ads to lower quality auctions at higher costs, significantly increasing customer acquisition costs and overstating the company's financial strength.